Description: A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors
Target Patient Population: Solid tumors
Study Design: Drug is given orally daily. Part 1A will be monotherapy and Part 1B will be in combination with Sasanlimab